Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

AbbVie discloses novel TNF-alpha modulators

Oct. 31, 2016

FDA issues complete response letter for sarilumab for rheumatoid arthritis

Oct. 31, 2016

First phase IIa trial of Medivir's MIV-711 fully enrolled, cleared to procede

Oct. 28, 2016

MYH3 gene variants may cause congenital scoliosis

Oct. 27, 2016

Boehringer Ingelheim discloses topline data from phase III trial of BI-695501

Oct. 27, 2016

Genetic variants in genes related to pain sensitivity may have a role in EDS

Oct. 25, 2016

Merck & Co. patents BTK inhibitors

Oct. 24, 2016

Merck & Co. describes novel azacarbazole derivatives

Oct. 21, 2016

FDA grants rare pediatric disease designation to Kuros Biosciences' KUR-112

Oct. 21, 2016

Fujifilm Kyowa Kirin Biologics reports phase III results for adalimumab biosimilar FKB-327

Oct. 20, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...